Literature DB >> 1415040

The agglutinin response to whole-cell and acellular pertussis vaccines is Bordetella pertussis--strain dependent.

D A Blumberg1, E Pineda, J D Cherry, A Caruso, J V Scott.   

Abstract

OBJECTIVE: To determine the significance of the Bordetella pertussis strain used as the antigen in the agglutinin assay for the evaluation of pertussis vaccines.
DESIGN: Randomized, double-blind study.
SETTING: Health maintenance organization clinics, primary care clinic at a referral hospital, and private practices in Los Angeles County, California. PARTICIPANTS: Forty healthy infants. SELECTION PROCEDURES: Convenience sample.
INTERVENTIONS: Twenty infants received whole-cell pertussis-component diphtheria-tetanus-pertussis vaccine (DTP), and 70 infants received acellular pertussis-component diphtheria-tetanus-pertussis vaccine (APDT) at ages 2, 4, and 6 months. MEASUREMENTS: The agglutinin assay was performed using three separate B pertussis strain preparations: (1) strains 130 and 138 in equal quantities, the constituents of the DTP vaccine, (2) strain 460, and (3) strain Tohama, the constituent of the APDT vaccine.
RESULTS: The agglutinin titers were highly strain dependent; in both groups of vaccinees at both ages the Tohama values were highest, followed by strain 460 and then strains 130/138. The vaccine groups had comparable titers at age 2 months regardless of the assay antigen used. However, at age 7 months, after three immunizations, the DTP group geometric mean titer was more than 10 times greater than that of the ADPT group using strains 130/138, but only 2.6 times higher using strain 460 and almost equivalent using Tohama strain.
CONCLUSION: Vaccine group agglutinin value comparisons strongly depend on assay antigens used.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1415040     DOI: 10.1001/archpedi.1992.02160220034016

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  4 in total

1.  Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells.

Authors:  B M van den Berg; H Beekhuizen; F R Mooi; R van Furth
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

Review 2.  A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.

Authors:  S S Patel; A J Wagstaff
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 3.  What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories.

Authors:  N Guiso; G Berbers; N K Fry; Q He; M Riffelmann; C H Wirsing von König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-11-11       Impact factor: 3.267

Review 4.  Whole-cell pertussis vaccine in early infancy for the prevention of allergy in children.

Authors:  Gladymar Perez Chacon; Jessica Ramsay; Christopher G Brennan-Jones; Marie J Estcourt; Peter Richmond; Patrick Holt; Tom Snelling
Journal:  Cochrane Database Syst Rev       Date:  2021-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.